• Facebook
  • Rss
  • Twitter
  • Youtube
  • Store
  • Donate
  • 0Shopping Cart
NCCS - National Coalition for Cancer Survivorship
  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • COVID-19 Resources for Cancer Survivors
    • Order Our Resources
  • News
    • Cancer Convos Podcast
  • Events
    • Ellen L. Stovall Award
      • 2020 Stovall Awards
      • Honorees
      • Sponsors
      • Committees
      • Reception
      • Nominations
    • Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us
  • Search
  • Menu Menu

Year-End MATCH (DEADLINE Dec 31): Donate & Make a Difference | Donate

Discusses the Pros and Cons of BRCA Screening

WCOE: Dr. Susan Love Discusses the Pros and Cons of BRCA Screening

September 12, 2014/in Cancer News, Cancer Policy Blog Care Coordination, Quality Cancer Care, Survivorship Care NCCS News /by actualize
What Caught Our Eye (WCOE) Each week, we take a closer look at the cancer policy articles, studies, and stories that caught our attention.
Post by Ellen Stovall

Ellen Stovall, NCCS Senior Health Policy Advisor

There are as many questions as there are differences of opinion about what constitutes the best evidence when it comes to appropriate cancer screening and then appropriate treatment once a diagnosis of cancer is made. Patients who read about current research findings face the dilemma of sorting through these differences of opinion and considering how to apply that evidence when making an informed decision.

At NCCS, we advocate for all who are at risk for and/or diagnosed with any type of cancer. Our advocacy centers on assuring that standards and practices in oncology are based on the best evidence available so that patients receive the best quality of care across all settings – at cancer centers and hospitals, and in private oncology practices. And yet, the average patient is often least likely to understand the evidence before deciding on the appropriate screening and treatment. And while conflicting evidence is not unique to breast cancer, it is fair to suggest that no screening or diagnostic methods have been more controversial over the last couple of decades than those related to breast cancer.

The Importance of Raising the Right Questions

Facing Our Risk of Cancer Empowered (FORCE), which advocates for individuals and families affected by hereditary breast and ovarian cancer, recommends genetic counseling before testing, as such counseling helps individuals interpret and understand the evidence and decide whether testing is right for them. FORCE is currently considering the evidence, benefits, risks, and potential impacts of the proposal to change screening practices and points out that “many women who meet current national guidelines are not getting the recommended genetic counseling and testing—and have difficulty obtaining coverage of needed screening and/or preventive measures.”
This week, what caught our eye is an excellent blog by renowned cancer surgeon, researcher and advocate for women’s breast health, Dr. Susan Love. Dr. Love raises important questions prompted by recent recommendations regarding breast cancer screening. Her observations relate to the work of celebrated breast cancer researcher, Dr. Mary-Claire King and colleagues. Their pioneering work in 1990 identified the BRCA1 gene, an important scientific finding connecting the heritable mutation of that gene to an increased risk for both breast and ovarian cancer.

Love points to some newly published work by King in both the Journal of the American Medical Association and the Proceedings of the National Academy of Sciences wherein she suggests that BRCA testing should become a routine part of medical care. What caught our eye was Love’s blog illustrating the importance of the kind of questioning and analysis of current data to support another method of testing—whether for breast cancer or for any type of cancer where heritability or other genetic risk factors will likely predict a yet-to-be-discovered finding of cancer.

We call your attention to this article to recognize its value in helping individuals raise the right questions in order make decisions about appropriate screening for cancer. Moreover, this article is valuable for those of us who advocate for policies related to best evidence for screening and treatment for ALL cancers and for delivery and payment reforms that will support quality, evidence-based care.

Post by Ellen Stovall.
Tags: Cancer Survivorship, ePatient, patient first, quality, screening, What Caught Our Eye
Share this entry
  • Share on Facebook
  • Share on Twitter
https://canceradvocacy.org/wp-content/uploads/EllenStovall.jpg 321 800 actualize https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png actualize2014-09-12 13:55:052020-11-24 14:23:03WCOE: Dr. Susan Love Discusses the Pros and Cons of BRCA Screening
You might also like
NCCS Starburst 250px Health Care Roundup: ACA Anniversary Met with a Challenge; Coronavirus Coverage; and More
SFNThumbVideo NCCS CEO Shelley Fuld Nasso Introduces Our New Blog Series
NCCS Starburst Thumbnail WCOE: “Why I Hope to Die at 75” and a New IOM Report on Quality and End of Life Preferences
FacebookProfile3 WCOE: Genetic Testing for Cancer Survivors, Survivorship as a ‘Chronic Condition,’ Post-Treatment Neuropathy, Moonshot Funding
affordable care act NCCS Position Statement on Actions to Undermine ACA
20years Twenty Years Later Blog Series: Introducing the Seventh Principle of the Imperatives for Quality Cancer Care
LillieShockney Guest Post: Forgotten Survivors—Supporting the Needs of Patients with Advanced Cancers
NCCS Starburst Thumbnail Announcements at the American Urological Association Address Screening and Management of Prostate Cancer

Latest News

HHS Humphrey bldg 1200

NCCS, Cancer Groups Urge CMS to Withdraw Most Favored Nation (MFN) Medicare Part B Rule That Will Harm Patients and Reduce Access to Care

December 22, 2020
The National Coalition for Cancer Survivorship (NCCS) joined other member organizations…
Read more
https://canceradvocacy.org/wp-content/uploads/2017/10/HHS-Humphrey-bldg-1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2020-12-22 20:27:262021-01-04 21:38:15NCCS, Cancer Groups Urge CMS to Withdraw Most Favored Nation (MFN) Medicare Part B Rule That Will Harm Patients and Reduce Access to Care
NCCS Letter to HHS

NCCS Letter to HHS: Proposed Regulatory Review Rule Would Create Unnecessary Uncertainty for Patients

December 9, 2020
The National Coalition for Cancer Survivorship (NCCS) recently submitted comments…
Read more
https://canceradvocacy.org/wp-content/uploads/HHS-Humphrey-bldg-1200-1030x515-1.jpg 515 1030 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2020-12-09 17:30:502020-12-10 08:22:55NCCS Letter to HHS: Proposed Regulatory Review Rule Would Create Unnecessary Uncertainty for Patients
HHS Humphrey bldg 1200

NCCS Opposes Most Favored Nation (MFN) Rule: New Medicare Part B Drug Payment Model Will Harm Patients

December 3, 2020
The National Coalition for Cancer Survivorship (NCCS) opposes the Most Favored Nation…
Read more
https://canceradvocacy.org/wp-content/uploads/HHS-Humphrey-bldg-1200.jpg 600 1200 NCCS Staff https://canceradvocacy.org/wp-content/uploads/2020/06/NCCA-Logo.png NCCS Staff2020-12-03 21:26:462020-12-03 21:28:06NCCS Opposes Most Favored Nation (MFN) Rule: New Medicare Part B Drug Payment Model Will Harm Patients

Take Action

Stovall Award

The Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care is a unique opportunity for patients and survivors to recognize pioneers who are transforming the cancer care system.

Join CPAT

The NCCS Cancer Policy & Advocacy Team (CPAT) is a program for survivors and caregivers to learn about pressing policy issues that affect quality cancer care in order to be engaged as advocates in public policy around the needs of cancer survivors.

Share Your Story

NCCS represents the millions of Americans who share a common experience – the survivorship experience – living with, through and beyond a cancer diagnosis.

STAY CONNECTED

Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action

  • About
    • Our Mission
    • Our History
    • Our Leadership
      • Policy Advisors
    • Employment
    • Partnerships
    • Financial Information
  • Policy
    • Quality Cancer Care
    • Access to Care
    • Health Equity
    • Redefining Functional Status (RFS)
    • 2020 State of Cancer Survivorship Survey
    • Cancer Care Planning and Communications Act (CCPCA)
  • Get Involved
    • What is Advocacy?
    • Cancer Policy and Advocacy Team (CPAT)
    • Elevating Survivorship
    • Survivor Stories
    • Cancerversary
    • State Based Cancer Advocacy
  • Resources
    • Survivorship Checklist
    • Cancer Survival Toolbox
    • Telehealth
    • Publications
      • Talking With Your Doctor
      • Self Advocacy
      • Employment Rights
      • Remaining Hopeful
    • Taking Charge of Your Care
    • Care Planning for Cancer Survivors
    • Tools For Care Providers
    • COVID-19 Resources for Cancer Survivors
    • Order Our Resources
  • News
    • Cancer Convos Podcast
  • Events
    • Ellen L. Stovall Award
      • 2020 Stovall Awards
      • Honorees
      • Sponsors
      • Committees
      • Reception
      • Nominations
    • Cancer Policy Roundtable
      • Fall 2020 Cancer Policy Roundtable
      • Spring 2020 Cancer Policy Roundtable
    • Cancer Policy and Advocacy Team (CPAT) Symposium 2020
    • Webinars
  • Contact Us

National Coalition for Cancer Survivorship
8455 Colesville Road  |  Suite 930  |  Silver Spring, MD 20910
877-NCCS-YES  |  info@canceradvocacy.org
Privacy Policy  |  Terms and Conditions

Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.

NCCS and CLC Policy Comments: 2015 Physician Fee Schedule dome dome NCCS Offers Comments to the Centers for Medicare and Medicaid Innovation on...
Scroll to top

Harmar Brereton, MD

Founder
Northeast Regional Cancer Institute

 

“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”

—Karen M. Saunders
President, Northeast Regional Cancer Institute